Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Innate Biologics LLC has a very singular prosecution presence in Biotechnology & Pharmaceuticals with only 1 pending office action. This single action is assigned to 1 distinct examiner, CRUM, MARY ABOU NADER. The matter resides within 1 distinct art unit, reflecting a highly concentrated and limited current engagement with the USPTO. For a portfolio of this size, prosecution strategy is entirely dependent on the specific requirements and history of this one examiner and art unit.
CRUM, MARY ABOU NADER is the busiest examiner by default, holding the 1 pending office action. There is no broader data to suggest how other examiners might treat the company's technology, making this single interaction critical for the company's patent goals. Practitioners must focus all efforts on the specific preferences of CRUM, MARY ABOU NADER, as there are no other pending cases to provide alternative paths to allowance. The concentration in 1 distinct art unit further emphasizes the specialized nature of the technology currently under review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRUM, MARY ABOU NADER | 1 | 39.2% | +63.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19305204 | IMMUNOMODULATORY COMPOSITIONS AND METHODS | CRUM, MARY ABOU NADER | 69d |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19305204 | IMMUNOMODULATORY COMPOSITIONS AND METHODS | CRUM, MARY ABOU NADER | 1657 | §112DP | Final Rejection | 69d | Pending | Aug 20, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnate Biologics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mary Abou Nader Crum has the most, with 1 of Innate Biologics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
